Armed antibodies for cancer therapy

Research focus

The Neri group at ETH Zürich has worked for more than 20 years on the development and engineering of anti-cancer antibody therapeutics. In the context of the Immunocure Project, the Neri group will provide:

• Access to antibody phage technology for the generation of fully-human monoclonal antibodies
• Generation and characterization of universal CAR T cells, capable of selective recognition of hapten-modified ligands
• In vivo testing of promising therapeutic strategies in mouse models of cancer, with a special focus on antibody-cytokine fusions

Members:

• Dario Neri
• Jonathan Kiefer
• Christian Pellegrino